Trinity Biotech Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Gillard

Algemeen directeur

US$710.0k

Totale compensatie

Percentage CEO-salaris	66.6%
Dienstverband CEO	4yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01

Trinity Biotech appoints former GE executive Aris Kekedjian as CEO

Oct 03

At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?

Sep 01

Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M

Jun 30

Analyse CEO-vergoeding

Hoe is John Gillard's beloning veranderd ten opzichte van Trinity Biotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$20m
Jun 30 2024	n/a	n/a	-US$22m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$710k	US$473k	-US$37m
Sep 30 2023	n/a	n/a	-US$39m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$34m
Dec 31 2022	US$863k	US$452k	-US$44m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$593k	US$346k	-US$2m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$2m
Mar 31 2021	n/a	n/a	-US$2m
Dec 31 2020	US$312k	US$52k	-US$6m

Compensatie versus markt: De totale vergoeding ($USD 710.00K ) John } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.07K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Gillard (43 yo)

4yrs

Tenure

US$710,000

Compensatie

Mr. John Gillard is President & CEO of Trinity Biotech plc since December 17, 2023 and served as Chief Financial Officer since November 17, 2020 until December 17, 2023. He serves as Executive Director at...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Gillard	President	4yrs	US$710.00k	geen gegevens
Ronan O'Caoimh	Founder	no data	US$80.00k	5.14% $ 593.2k
James Walsh	Executive Director of Business Development & Executive Director	no data	US$50.00k	0.74% $ 85.0k
Louise Tallon	CFO & Chief Accounting Officer	less than a year	geen gegevens	geen gegevens
Jacqueline O'Neill	Director of Operations	no data	geen gegevens	geen gegevens
Gary Keating	Chief Technology Officer	no data	geen gegevens	geen gegevens
Eibhlin Kelly	Chief Information Officer	9.2yrs	geen gegevens	geen gegevens
Colm Molloy	Group Director of Human Resources & Culture	no data	geen gegevens	geen gegevens
Adrian Donohue	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TRIB wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Gillard	President	4yrs	US$710.00k	geen gegevens
Ronan O'Caoimh	Founder	2.1yrs	US$80.00k	5.14% $ 593.2k
James Walsh	Executive Director of Business Development & Executive Director	17.8yrs	US$50.00k	0.74% $ 85.0k
Andrew Omidvar	Independent Director	1.2yrs	US$10.00k	0% $ 0
Thomas Lindsay	Independent Non-Executive Director	2.1yrs	US$63.00k	0% $ 0

2.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TRIB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Trinity Biotech Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Trinity Biotech plc, Annual General Meeting, Sep 30, 2024

Trinity Biotech plc Appoints Global Life Sciences Leader Adrian Donohue as Chief Commercial Officer

Trinity Biotech Appoints David Ouston as Biosensor Marketing Director

Trinity Biotech plc Announces Chief Financial Officer Changes

Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Trinity Biotech plc Announces CEO Changes

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Trinity Biotech plc to Report Q3, 2024 Results on Nov 15, 2024

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Trinity Biotech plc (NasdaqGS:TRIB) acquired EpiCapture Limited for $3.6 million.

Trinity Biotech plc Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Second quarter 2024 earnings: EPS misses analyst expectations

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Trinity Biotech plc (NasdaqGS:TRIB) acquired Metabolomic Diagnostics Ltd. for an enterprise value of $1.3 million.

Trinity Biotech plc to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

Trinity Biotech plc Provides Update on the Continued Development of its Glucose Biosensor Technology

Trinity Biotech plc, Annual General Meeting, Sep 30, 2024

Trinity Biotech plc Appoints Global Life Sciences Leader Adrian Donohue as Chief Commercial Officer

Trinity Biotech Appoints David Ouston as Biosensor Marketing Director

Second quarter 2024 earnings: Revenues in line with analyst expectations

Trinity Biotech plc to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Trinity Biotech Obtains an Extension to Demonstrate Compliance with Nasdaq Listing Requirements

Trinity Biotech plc Provides Preliminary Revenue Guidance for the Second Quarter of 2024

Trinity Biotech plc has filed a Follow-on Equity Offering in the amount of $5.5 million.

Trinity Biotech plc has filed a Follow-on Equity Offering in the amount of $5.5 million.

Trinity Biotech plc Announces Chief Financial Officer Changes

Trinity Biotech plc to Begin European Pre-Pivotal Trial to Optimize Its Cgm Sensor

New minor risk - Share price stability

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Trinity Biotech plc Launches Its Continuous Glucose Monitoring Microsite to Showcase Its Innovative & Differentiated Technology

Trinity Biotech plc Receives A Staff Determination Letter Regarding MVPHS Requirement by May 20, 2024

Trinity Biotech plc to Report Q1, 2024 Results on May 23, 2024

Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024

Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Full year 2023 earnings released: US$4.82 loss per share (vs US$6.46 loss in FY 2022)

Full year 2023 earnings released

Trinity Biotech plc to Report Q4, 2023 Results on Apr 04, 2024

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

New minor risk - Shareholder dilution

New major risk - Share price stability

Trinity Biotech plc Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released

Trinity Biotech to Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

Trinity Biotech plc Announces CEO Changes

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Trinity Biotech plc Appoints Andrew Omidvar as Director

Consensus EPS estimates fall by 47%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2023

Trinity Biotech plc to Report Q2, 2023 Results on Oct 03, 2023

Now 20% undervalued after recent price drop

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Trinity Biotech plc, Annual General Meeting, Sep 29, 2023

Trinity Biotech plc Announces Receives 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Consensus revenue estimates fall by 17%

New minor risk - Profitability

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Trinity Biotech plc to Report Q1, 2023 Results on Jul 06, 2023

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Consensus revenue estimates fall by 11%

Full year 2022 earnings: Revenues in line with analyst expectations

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 54%

Trinity Biotech plc to Report Q3, 2022 Results on Dec 15, 2022

Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.037 loss in 2Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released

Trinity Biotech plc Provides Revenue Guidance for the Third Quarter of 2022

Trinity Biotech plc to Report Q2, 2022 Results on Nov 03, 2022